Enanta Pharmaceuticals Inc (ENTA) Holdings Boosted by Alps Advisors Inc.

Alps Advisors Inc. grew its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 19.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,684 shares of the biotechnology company’s stock after purchasing an additional 6,549 shares during the period. Alps Advisors Inc. owned approximately 0.20% of Enanta Pharmaceuticals worth $3,391,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. increased its position in Enanta Pharmaceuticals by 2.9% during the 2nd quarter. BlackRock Inc. now owns 2,433,000 shares of the biotechnology company’s stock worth $281,985,000 after purchasing an additional 68,564 shares during the period. Rhumbline Advisers increased its position in Enanta Pharmaceuticals by 1.9% during the 2nd quarter. Rhumbline Advisers now owns 37,550 shares of the biotechnology company’s stock worth $4,352,000 after purchasing an additional 691 shares during the period. ClariVest Asset Management LLC increased its position in Enanta Pharmaceuticals by 98.7% during the 2nd quarter. ClariVest Asset Management LLC now owns 21,661 shares of the biotechnology company’s stock worth $2,510,000 after purchasing an additional 10,761 shares during the period. Zeke Capital Advisors LLC acquired a new position in Enanta Pharmaceuticals during the 2nd quarter worth approximately $216,000. Finally, Acadian Asset Management LLC increased its position in Enanta Pharmaceuticals by 72.4% during the 2nd quarter. Acadian Asset Management LLC now owns 381,729 shares of the biotechnology company’s stock worth $44,242,000 after purchasing an additional 160,344 shares during the period. Institutional investors own 78.25% of the company’s stock.

ENTA has been the topic of several recent analyst reports. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research report on Thursday, August 9th. JMP Securities reiterated a “buy” rating and set a $120.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, July 31st. BidaskClub cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Oppenheimer set a $100.00 price target on Enanta Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, August 14th. Finally, UBS Group cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $104.00.



ENTA opened at $76.99 on Friday. The company has a market capitalization of $1.47 billion, a P/E ratio of 84.60 and a beta of 0.80. Enanta Pharmaceuticals Inc has a 1-year low of $44.52 and a 1-year high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing analysts’ consensus estimates of $0.98 by ($0.01). The firm had revenue of $57.26 million during the quarter, compared to analyst estimates of $56.59 million. Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. Analysts expect that Enanta Pharmaceuticals Inc will post 3.56 earnings per share for the current year.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,155 shares of the stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $95.32, for a total transaction of $396,054.60. Following the sale, the vice president now owns 4,155 shares in the company, valued at approximately $396,054.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tim Ocain sold 25,000 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $83.64, for a total value of $2,091,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,310 shares of company stock worth $2,870,644. Insiders own 10.56% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

See Also: Understanding Average Daily Trade Volume

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply